Compounders Research Compare

Alzamend Neuro Inc(ALZN)

Biotechnology · Atlanta, GA

$1.39-0.02 (-1.42%)

Delayed quote: Oct 6, 2026, 12:25 PM EDT

About Alzamend Neuro Inc

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Atlanta, GA

6 employees

www.alzamend.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Stephan Jackman

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T16:35:35.486Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:35:35.486Z.

Quote observation: 2026-10-06T16:25:40.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 5,288,589
Total debt · period ending 2026-07-31: 0
Cash · period ending 2026-07-31: 7,591,444
TTM free cash flow · period ending 2026-07-31: -6,843,544

FMP input reference: 92c64d45da0f6188a1f90128b536bb11be3c3b1eef81eadefd65dadb391e1e70

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ALZN EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

ALZN Competitors' EV/FCF Ratio

Alzamend Neuro Inc

Current

Market Cap

$5.29M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Intelligent Bio Solutions Inc.

Market Cap

$5.29M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Soligenix, Inc.

Market Cap

$5.34M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Gelteq Limited Ordinary Shares

Market Cap

$5.23M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Liminatus Pharma, Inc. Class A Common Stock

Market Cap

$5.23M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lunai Bioworks Inc.

Market Cap

$5.21M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Basel Medical Group Ltd Ordinary Shares

Market Cap

$5.20M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Pulmatrix, Inc.

Market Cap

$5.41M

EV/FCF Ratio

N/A

TTM Avg

1.32x

3Y Avg

1.32x

5Y Avg

1.32x

Imunon, Inc.

Market Cap

$5.02M

EV/FCF Ratio

N/A

TTM Avg

11.91x

3Y Avg

14.69x

5Y Avg

14.69x

Acurx Pharmaceuticals, Inc.

Market Cap

$5.59M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Alzamend Neuro Inc (ALZN)	$5.29M	N/A	N/A	N/A	N/A
Intelligent Bio Solutions Inc. (INBS)vs ›	$5.29M	N/A	N/A	N/A	N/A
Soligenix, Inc. (SNGX)vs ›	$5.34M	N/A	N/A	N/A	N/A
Gelteq Limited Ordinary Shares (GELS)vs ›	$5.23M	N/A	N/A	N/A	N/A
Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs ›	$5.23M	N/A	N/A	N/A	N/A
Lunai Bioworks Inc. (LNAI)vs ›	$5.21M	N/A	N/A	N/A	N/A
Basel Medical Group Ltd Ordinary Shares (BMGL)vs ›	$5.20M	N/A	N/A	N/A	N/A
Pulmatrix, Inc. (PULM)vs ›	$5.41M	N/A	1.32x	1.32x	1.32x
Imunon, Inc. (IMNN)vs ›	$5.02M	N/A	11.91x	14.69x	14.69x
Acurx Pharmaceuticals, Inc. (ACXP)vs ›	$5.59M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics